Skip to main content

Table 3 The incidence of TRAEs in TGC group

From: The efficacy and safety of tislelizumab combined with gemcitabine plus cisplatin in the treatment of postoperative patients with muscle-invasive upper tract urothelial carcinoma

 

TGC(n = 30)

Grade = 1

Grade = 2

Grade = 3

Patients with TRAEs

21(70.0%)

4(13.3%)

3(10%)

leukopenia

10(33.3%)

1(3.3%)

2(6.7%)

Anemia

15(50.0%)

2(6.7%)

0

thrombocytopenia

6(20.0%)

1(3.3%)

0

elevated creatinine

5(16.7%)

0

0

Nausea/vomiting

8(26.7%)

0

1(3.3%)

Diarrhea

2(6.7%)

0

0

Pruritus

7(23.3%)

0

0

Fatigue

7(23.3%)

1(3.3%)

0

  1. TGC: tislelizumab combined with gemcitabine plus cisplatin
  2. TRAEs: treatment related adverse events
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us